Alvotech (ALVO) shares rallied 8.6% in the last trading session to close at $8.7. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% loss over the past four weeks.Alvotech extended its rally for a second day, fueled by optimism after the EMA’s CHMP backed its regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and J&J’s Simponi.This company is expected to post quarterly earnings of $0.08 per ...

Core Viewpoint - Pfizer plans to acquire Metsera for $4.9 billion, with potential total value reaching $7.3 billion including milestone payments, aiming to strengthen its position in the obesity drug market projected to be worth $100 billion by 2030 [1][3]. Group 1: Acquisition Details - The acquisition price is set at $47.50 per share, with milestone payments potentially increasing the total to $70 per share [1]. - Metsera's stock surged by 60% to over $50 following the acquisition announcement, while Pfizer's stock remained stable around $24 [2]. - Pfizer will finance the acquisition through cash and debt, while maintaining its dividend and capital priorities [2]. Group 2: Market Context - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, with Eli Lilly's Zepbound controlling over 50% of the market and achieving an average weight reduction of 20.2%, compared to Novo Nordisk's Wegovy at 13.5% [4]. - Pfizer previously discontinued its own obesity drug, danuglipron, due to safety concerns [4]. Group 3: Financial Implications - The acquisition could help Pfizer mitigate the impact of upcoming patent expirations for key drugs like Eliquis and Ibrance [5]. - Metsera has raised $316.2 million through its IPO but is not expected to generate significant revenue in the near future [6]. - Pfizer's total sales are projected to slightly increase to $63.81 billion in the current year, with a slight decline expected in FY26 [12]. Group 4: Drug Pipeline - Metsera's MET-097i weight loss drug is in phase two trials, targeting hormones for weight loss and type 2 diabetes treatment [7]. - Metsera's MET-233i drug has shown promising results with an average weight loss of 8.4% in the first five weeks of phase 1 trials [7]. Group 5: Earnings Projections - Pfizer's EPS for FY25 is projected to increase to $3.14, while FY26 EPS is expected to decline to $3.08 [12]. - Metsera's FY25 EPS estimates have improved to a projected loss of -$2.79 per share, but FY26 estimates have worsened to -$3.64 [16].

Core Insights - Micron reported a revenue of $11.32 billion for the quarter ended August 2025, marking a 46% increase year-over-year, with EPS at $3.03 compared to $1.18 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $11.26 billion by 0.47%, and the EPS also surpassed the consensus estimate of $2.86 by 5.94% [1] Revenue Breakdown - DRAM revenue was $8.98 billion, exceeding the average estimate of $8.8 billion, representing a year-over-year increase of 68.7% [4] - Other technology revenue (primarily NOR) was $79 million, above the average estimate of $74.88 million, reflecting a year-over-year growth of 33.9% [4] - NAND revenue was $2.25 billion, slightly below the average estimate of $2.35 billion, showing a year-over-year decline of 4.8% [4] Stock Performance - Micron's shares have returned 41.4% over the past month, significantly outperforming the Zacks S&P 500 composite's 3.6% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]

Company Performance - Intrusion Inc. closed at $1.89, reflecting a -3.08% change from the previous day, underperforming the S&P 500's loss of 0.55% [1] - Over the past month, shares of Intrusion Inc. gained 8.33%, which is below the Computer and Technology sector's gain of 9.88% but above the S&P 500's gain of 3.64% [1] Upcoming Earnings - Analysts expect Intrusion Inc. to report earnings of -$0.1 per share, indicating a year-over-year growth of 71.43% [2] - The Zacks Consensus Estimate for revenue is projected at $1.91 million, representing a 27.33% increase from the previous year [2] Full Year Estimates - For the full year, analysts anticipate earnings of -$0.38 per share and revenue of $7.74 million, reflecting changes of +76.69% and +34.03% respectively from last year [3] Analyst Estimates - Recent modifications to analyst estimates for Intrusion Inc. indicate shifting business dynamics, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Intrusion Inc. at 4 (Sell) [6] Industry Context - The Computer - Networking industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 50, placing it in the top 21% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Sunrun is experiencing fluctuations in its stock price, with a recent decline of 6.59%, while the company is expected to report significant earnings growth in its upcoming earnings report [1][2]. Company Performance - Sunrun's stock closed at $16.45, down 6.59% from the previous trading session, underperforming the S&P 500, which lost 0.55% [1]. - Over the past month, Sunrun's shares have increased by 7.51%, outperforming the Oils-Energy sector's gain of 1.1% and the S&P 500's gain of 3.64% [1]. Earnings Expectations - The upcoming earnings report is anticipated to show an EPS of $0.03, representing a 108.11% increase year-over-year [2]. - Revenue is expected to reach $606.24 million, indicating a 12.86% increase compared to the same quarter of the previous year [2]. Full Year Projections - For the full year, earnings are projected at $0.71 per share, reflecting a decrease of 46.62% from the previous year, while revenue is expected to be $2.27 billion, showing an increase of 11.2% [3]. Analyst Estimates - Recent changes to analyst estimates for Sunrun are being closely monitored, as upward revisions typically indicate positive sentiment regarding the company's business operations and profit generation capabilities [4]. Zacks Rank and Valuation - Sunrun currently holds a Zacks Rank of 1 (Strong Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6]. - The company is trading at a Forward P/E ratio of 24.81, which is higher than the industry average Forward P/E of 17.09 [7]. Industry Context - The Solar industry, part of the Oils-Energy sector, has a Zacks Industry Rank of 43, placing it in the top 18% of over 250 industries [7]. - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [8].

Company Performance - Sweetgreen, Inc. closed at $8.34, reflecting a decline of 5.98% from the previous day, underperforming the S&P 500's loss of 0.55% [1] - Over the past month, shares of Sweetgreen have decreased by 2.53%, while the Retail-Wholesale sector gained 1.22% and the S&P 500 increased by 3.64% [1] Upcoming Financial Results - The company is expected to report an EPS of -$0.16, which represents an 11.11% increase compared to the same quarter last year [2] - Revenue is anticipated to be $183.58 million, indicating a 5.85% rise from the year-ago quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$0.71 per share and revenue at $713.85 million, reflecting increases of 10.13% and 5.47% respectively from the prior year [3] Analyst Estimates and Confidence - Recent changes to analyst estimates for Sweetgreen should be noted, as positive revisions indicate analysts' confidence in the company's performance and profit potential [4] - The Zacks Rank system, which evaluates these estimate changes, currently ranks Sweetgreen at 4 (Sell) [6] Industry Context - Sweetgreen operates within the Retail - Restaurants industry, which holds a Zacks Industry Rank of 184, placing it in the bottom 26% of over 250 industries [7]

Company Performance - Steel Dynamics (STLD) closed at $136.69, down 1.71% from the previous trading session, underperforming the S&P 500's loss of 0.55% [1] - Over the past month, shares of Steel Dynamics gained 4.34%, slightly trailing the Basic Materials sector's gain of 4.52% and outperforming the S&P 500's gain of 3.64% [1] Upcoming Earnings - The earnings report for Steel Dynamics is scheduled for October 20, 2025, with projected earnings per share (EPS) of $2.66, indicating a 29.76% increase year-over-year [2] - The Zacks Consensus Estimate for revenue is $4.7 billion, reflecting an 8.26% increase from the same quarter last year [2] Full Year Projections - For the full year, the Zacks Consensus Estimates project earnings of $8.93 per share and revenue of $18.34 billion, representing changes of -9.25% and +4.54% from the prior year, respectively [3] - Recent revisions to analyst forecasts are important as they reflect near-term business trends, with positive changes indicating a favorable outlook on business health and profitability [3] Valuation Metrics - Steel Dynamics has a Forward P/E ratio of 15.57, which is a premium compared to the industry average Forward P/E of 14.14 [6] - The company has a PEG ratio of 1.13, while the Steel - Producers industry has an average PEG ratio of 0.78 [6] Industry Context - The Steel - Producers industry is part of the Basic Materials sector and currently holds a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [7] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

MakeMyTrip (MMYT) ended the recent trading session at $96.70, demonstrating a -5.07% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.55%. On the other hand, the Dow registered a loss of 0.19%, and the technology-centric Nasdaq decreased by 0.95%. Heading into today, shares of the online travel company had lost 0.39% over the past month, lagging the Computer and Technology sector's gain of 9.88% and the S&P 500's gain of 3.64%.The investment community will be p ...

American Airlines (AAL) closed at $12.19 in the latest trading session, marking a -1.14% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.55%. On the other hand, the Dow registered a loss of 0.19%, and the technology-centric Nasdaq decreased by 0.95%. Heading into today, shares of the world's largest airline had lost 5.15% over the past month, lagging the Transportation sector's loss of 2.32% and the S&P 500's gain of 3.64%.Investors will be eagerly watching for the ...

Teladoc (TDOC) ended the recent trading session at $8.37, demonstrating a +2.2% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.19%, and the tech-heavy Nasdaq lost 0.95%. The telehealth services provider's shares have seen an increase of 6.78% over the last month, surpassing the Medical sector's loss of 0.2% and the S&P 500's gain of 3.64%.The upcoming earnings release of Teladoc will be of great interest to investors. The ...